Akari Therapeutics PLC AKTX

US Biotechnology

$7.86 ▼ -1.75% ($-0.14)

🗓️ Earnings Next Week

Open $7.80

Prev Close $8.00

Day Range $7.80 – $8.10

52W Range $3.02 – $49.60

Market Cap $9.16M

Beta 1.40

EPS (TTM) $-0.01

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-01-31
Shares Out.	3,569,610,000
Website	akaritx.com/ ↗
Phone	19292747510
Employees	5
Net Income	-$14.5M
Total Assets	$33.9M
Total Liabilities	$19.5M
Equity	$14.4M

About Akari Therapeutics PLC

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Akari Therapeutics PLC is a publicly traded company under the ticker symbol AKTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.